MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis

Molecular or proteomic biomarker tests for assessing liver fibrosis are covered for adults (>=18) with suspected or diagnosed MASLD/MASH when non-molecular risk assessment does not indicate low risk (e.g., FIB-4 >=1.3), LSM is indeterminate or not done, and test results will directly inform documented management decisions. Coverage requires published clinical validity with reproducible results, independent algorithm validation if applicable, completion of a MolDX Technical Assessment, and testing is limited to once per 12 months and not within 12 months after a liver biopsy; tests for other chronic liver disease etiologies are excluded.

"Adult (age >=18) with clinical suspicion or diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH) per current prof..."

Sign up to see full coverage criteria, indications, and limitations.